← Back to Screener
Pelthos Therapeutics Inc. (PTHS)
Price$22.95
Favorite Metrics
Price vs S&P 500 (26W)-23.95%
Price vs S&P 500 (4W)1.48%
Market Capitalization$77.23M
All Metrics
Book Value / Share (Quarterly)$18.85
Cash Flow / Share (Quarterly)$-5.50
Price vs S&P 500 (YTD)-29.02%
EPS (TTM)$-20.71
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-20.71
EPS (Annual)$-23.04
Gross Margin (Annual)76.25%
Cash / Share (Quarterly)$4.60
ROA (Last FY)-7657.22%
EBITD / Share (TTM)$-16.63
Cash Flow / Share (Annual)$-9.49
P/B Ratio1.33x
P/B Ratio (Quarterly)1.47x
Net Income / Employee (Annual)$-11
Net Interest Coverage (TTM)-1.82x
ROA (TTM)-72.82%
EPS Incl Extra (Annual)$-23.04
Current Ratio (Annual)0.34x
Quick Ratio (Quarterly)0.97x
3-Month Avg Trading Volume0.01M
52-Week Price Return70.48%
Tangible BV / Share (Quarterly)$8.33
P/S Ratio (Annual)4.60x
Asset Turnover (Annual)2.78x
52-Week High$54.29
EPS Excl Extra (Annual)$-23.04
26-Week Price Return-15.20%
Quick Ratio (Annual)0.32x
13-Week Price Return-9.92%
Current Ratio (Quarterly)2.01x
Enterprise Value$63.025
Revenue / Employee (Annual)$4
Pretax Margin (Annual)-301.91%
Cash / Share (Annual)$0.84
3-Month Return Std Dev90.21%
Net Income / Employee (TTM)$-11
Net Interest Coverage (Annual)-1.82x
EPS Basic Excl Extra (Annual)$-23.04
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-20.71
Revenue / Share (Annual)$8.93
Price vs S&P 500 (52W)35.39%
Year-to-Date Return-25.76%
5-Day Price Return0.07%
EPS Normalized (Annual)$-23.04
Net Profit Margin (Annual)-257.93%
Month-to-Date Return9.54%
EBITD / Share (Annual)$-16.57
Operating Margin (Annual)-194.79%
EPS Basic Excl Extra (TTM)$-20.71
P/TBV (Quarterly)3.34x
Price vs S&P 500 (13W)-12.79%
Beta0.43x
52-Week Low$9.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.18
4.17
4.17
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PTHSPelthos Therapeutics Inc. | — | — | — | — | $22.95 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Pelthos Therapeutics is a clinical-stage biotechnology company developing non-opioid pain therapeutics by targeting the NaV1.7 sodium ion channel. The company's pipeline focuses on treating chronic visceral pain, acute and chronic eye pain, and post-surgical nerve pain. Lead candidates include CC8464 and CT2000, with CT2000 specifically targeting acute and chronic dry eye disease.